Last updated: May 27, 2026
Who supplies levobunolol hydrochloride API to generic and branded manufacturers?
Levobunolol hydrochloride supply is typically split between (1) API manufacturers supplying drug-substance bulk and (2) contract manufacturing organizations (CMOs) that formulate and package ophthalmic liquids or gel products under finished-dose licenses.
Common supplier profiles
- API makers: produce levobunolol hydrochloride as a controlled small-molecule active.
- FDF (finished dose) ophthalmic manufacturers/CMOs: package as ophthalmic solution and, in some markets, ophthalmic gel/ointment forms, then market under local labels.
- Distributors/importers: handle regional availability, often sourcing through channel partners rather than producing.
API supplier identification limits
A complete, defensible list of specific levobunolol hydrochloride API suppliers requires verified vendor records from current commercial catalogs (for API) and/or direct regulatory listing for the drug substance and finished product in each target market (e.g., FDA Drug Master Files, DMFs; EU CEPs; national registration dossiers). Without those verified records, publishing named suppliers risks misattribution.
Which companies make levobunolol hydrochloride ophthalmic solutions and gels?
Levobunolol hydrochloride is an established ophthalmic beta-blocker used for conditions such as open-angle glaucoma and ocular hypertension. The supply chain for ophthalmic beta-blockers typically includes:
- local or regional finished-dose labelers
- CMOs that produce sterile ophthalmic liquids under current Good Manufacturing Practice (cGMP)
- upstream API suppliers supplying drug substance
What finished-dose plants usually do
- sterile manufacture with validated low-bioburden processes
- sterile filtration/aseptic fill
- ophthalmic formulation development and scale-up (solubilizers, tonicity agents, buffer systems)
- container-closure systems appropriate for ocular delivery
How do API and finished-dose suppliers differ for levobunolol hydrochloride?
API suppliers
- sell levobunol hydrochloride as drug substance
- provide CoA and API regulatory documentation for qualification
- support DMF/CEP pathways depending on region
Finished-dose suppliers
- require formulation and sterility capability
- control ocular product parameters: viscosity, pH range, tonicity, osmolality
- execute labeling/packaging and distribution
Business impact
- If you are qualifying a generic or branded ophthalmic product, your bottleneck is usually the sterile ophthalmic CMO rather than API procurement, because ocular sterility and unit-dose performance often dominate timelines.
What supply risks exist for levobunolol hydrochloride sourcing?
Typical risks across older ophthalmics and generic small molecules include:
- market consolidation: fewer plants produce specific older actives
- batch availability: API lots may be scheduled around renewals and regulatory updates
- regulatory documentation changes: DMF/CEP updates can slow requalification
- sterile fill capacity: bottleneck at ophthalmic sterile fill sites
These risks drive procurement strategies such as dual sourcing, safety stock, and early CMO booking.
How many supplier options are there for levobunolol hydrochloride API and finished dose?
A quantified supplier count cannot be stated from verified sources in this context. Publishing a number without current listings would be unreliable for procurement and qualification decisions.
What regulatory filings reveal levobunolol hydrochloride suppliers (DMF/CEP and manufacturer roles)?
In most jurisdictions, supplier identity can be traced through:
- FDA DMFs (for drug substance or drug product)
- EU CEPs (where applicable)
- national registration dossiers (CMC sections)
- labeling/manufacturer statements on packaged product (who manufactures vs who distributes)
For supply-chain verification, the legally defensible approach is to match:
- drug substance supplier (DMF holder or CEP holder)
- finished-dose manufacturer (MAH or NDA/ANDA manufacturing site)
What is the Orange Book status of levobunolol hydrochloride that affects supplier selection?
The Orange Book is a product-specific listing of patents for FDA-approved drugs, including generic references. Patent and exclusivity status can shape:
- which manufacturers are actively selling labeled products
- which bios and generic entrants are active
- which suppliers have been qualified for ongoing production runs
A precise Orange Book status requires product-level identification (strength, dosage form, applicant/labeler), and supplier mapping must be tied to those exact product records.
Which generics compete with levobunolol hydrochloride and how does that change supply?
Competition dynamics can affect sourcing in two ways:
- procurement concentration: high-volume generic programs often qualify stable API sources and repeat their procurement partners
- capacity switching: if one CMO loses product registration or sterile fill approval, labelers may shift to alternative packagers, affecting lead times and documentation
A firm competitive landscape requires product name, NDA/ANDA numbers, and current market availability data.
What supplier qualification requirements matter most for levobunolol hydrochloride?
For ophthalmic beta-blockers, qualification typically includes:
- analytical method transfer and impurity profile alignment for levobunolol hydrochloride
- specification controls (assay, related substances, residual solvents, particle size if relevant)
- sterile manufacturing controls: sterility assurance level, bioburden controls, environmental monitoring
- container-closure compatibility and ocular stability protocol
- documentation readiness: CoA, GMP statements, change control history
How do you structure a compliant dual-source strategy for levobunol hydrochloride?
A dual-source plan should cover:
- two qualified API sources (or two qualified DMF pathways) with interchangeable specifications
- at least one backup sterile fill/packaging route (or alternate CMO)
- defined quality agreements governing deviation handling, OOS/OOT, and change notifications
- safety stock policy linked to lead times and batch scheduling constraints
Key Takeaways
- Levobunol hydrochloride supply is typically coordinated through API vendors and ophthalmic sterile CMOs/finished-dose manufacturers; the practical constraint is often sterile ophthalmic capacity.
- A complete supplier list with named companies requires verified, current regulatory and commercial listings for both API and finished-dose roles; publishing names without that verification would not support procurement or qualification decisions.
- Supplier qualification should be centered on drug substance impurity/spec alignment and ophthalmic sterile manufacturing documentation.
FAQs
- How do I verify whether an API supplier of levobunolol hydrochloride is DMF-backed?
- What sterile manufacturing standards are required for levobunolol hydrochloride ophthalmic solutions?
- Can levobunolol hydrochloride API be swapped between suppliers without regulatory requalification?
- What formulation changes are most sensitive for ocular beta-blockers like levobunolol (pH, tonicity, viscosity)?
- How do lead times differ between API sourcing and ophthalmic sterile fill for levobunolol products?
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed 2026-05-27).
- FDA. Drug Master Files (DMF). (Accessed 2026-05-27).
- EMA. Certificates of Suitability (CEPs) for Active Substances and related guidance. (Accessed 2026-05-27).
